Immunogen, Inc.
Period Ending Jun 30, 2013 Jun 30, 2012 Jun 30, 2011 Jun 30, 2010
Total Revenue 35,535 16,357 19,305 13,943
Cost of Revenue - - - -
Gross Profit 35,535 16,357 19,305 13,943
Operating Expenses
Research and Development 87,073 69,192 63,453 50,280
Sales, General and Admin. 21,471 20,422 16,040 14,898
Non-Recurring Items - - - -
Other - - - -
Operating Income (73,009) (73,257) (60,188) (51,235)
Income From Continuing Operations
Add'l Income/Expense Items 198 (62) 1,914 58
Earnings Before Interest and Tax (72,811) (73,319) (58,274) (51,177)
Interest Expense - - - -
Earnings Before Tax (72,811) (73,319) (58,274) (51,177)
Income Tax - - - (265)
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (72,811) (73,319) (58,274) (50,912)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (72,811) (73,319) (58,274) (50,912)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (72,811) (73,319) (58,274) (50,912)